We pioneer breakthroughs in healthcare. For everyone. Everywhere.
Siemens Healthineers is a leading medical technology company with over 125 years of experience. Our product and service portfolio which is continuously developing from in-vitro and in-vivo diagnostics, is crucial for clinical decision-making and treatment pathways. With AI-supported applications and digital offerings this plays an increasingly important role in the next generation of medical innovations and means we are well positioned to take on the biggest challenges in healthcare.
Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. Further information is available at www.siemens-healthineers.co.uk/poc
Our Point-of-Care Testing is designed to provide immediate, convenient, and easy-to-use diagnostic testing.
From the emergency department to primary care, clinical management decisions can be made immediately and result in improved patient safety, clinical outcomes, and overall patient satisfaction.
Should you wish to discuss any of our solutions please email: poc.team@siemens-healthineers.com and a member of our team will come back to you.
Siemens Healthineers offers a wide variety of Point of Care products and connectivity solutions. To view in more detail, please click the button below:
Siemens VTLi Patient-side Immunoassay Analyzer
Customer Testimonial - Loughborough Urgent Treatment Centre
Siemens Healthineers High-sensitivity Troponin I testing with a simple fingerstick. Results in only 8 minutes at the patient’s side. Discover how Loughborough Urgent Treatment Centre are using the Atellica VTLi as part of their standard model to assess chest pain here
POC Atellica VTLI hs-cTnI assay promises to enable safe and efficient risk assessment and management of suspected ACS patients
We are excited to share the 2024 European Heart Journal publication highlighting the safety and remarkable effectiveness of the Atellica® VTLi high-sensitivity troponin assay for the management of suspected ACS patients.
The publication, titled Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 hour¹ and authored by Professor Louise Cullen (Queensland, Australia) et al., describes the derivation and validation of a 0–2 h algorithm, as recommended by the ESC guidelines, for the assessment of patients with suspected acute myocardial infarction (AMI) using the Atellica VTLi hs-cTnI assay with results in just 8 minutes. The Atellica VTLi hs-cTnI assay is the only POC hs-cTnI assay to date to have the validation of the rapid diagnostic algorithm thresholds in whole blood.
With demonstrated safety and effectiveness in independent prospective and interventional studies, the Atellica VTLi System has the potential to transform the management of suspected ACS patients.
As reported by Cullen et al. in EHJ, up to two-thirds of suspected ACS patients could be safely dispositioned as low risk by the Atellica® VTLi hs-cTnI assay with ≥ 99.9% NPV (negative predictive value), potentially resulting in resource optimisation and hospital length of stays, enhancing patient care.
To learn more about how the Atellica VTLi analyser can enhance patient care and improve outcomes in your emergency department, download the full article by visiting our webpage.
1. Cullen et al. Point-of-care high-sensitivity cardiac troponin in suspected acute myocardial infarction assessed at baseline and 2 h European Heart Journal (2024) 00, 1–8
The products/features mentioned here are not commercially available in all countries. Not available for sale in the U.S.A. Their future availability cannot be guaranteed.
Latest innovation in diabetes care from Siemens Healthineers optimises diabetes management and enables early diagnosis
With diabetes cases on the rise globally1, early detection and management are critical to prevent health complications that occur when chronic conditions are left unmanaged.
The compact Atellica DCA Analyser delivers lab equivalent HbA1c and ACR results in minutes and provides flexibility both in its design and its workflow capabilities.
On demand testing minimises barriers to care by ensuring patients receive timely medical guidance without the need for additional appointments.
Siemens Healthineers has introduced its latest diabetes care innovation, the next-generation point-of-care Atellica DCA Analyser. Designed to optimise diabetes management and enable early diagnosis, the analyser empowers clinicians to conduct HbA1c and ACR testing at the point of care, delivering results within minutes. With diabetes cases on the rise, early detection and management are critical, yet nearly half of people with diabetes are undiagnosed.1 The Atellica DCA Analyser addresses key challenges such as large patient volumes and limited space, ensuring patients receive timely medical guidance and helping to remove the need for additional appointments.
Used for diagnosing and monitoring diabetes, the compact Atellica DCA Analyser produces HbA1c and ACR results in minutes and provides flexibility both in its design and workflow capabilities. Possessing a small footprint while maintaining the accuracy of central laboratory methods, the Atellica DCA Analyser is suitable for any testing environment. Clinicians can deliver care with confidence as proprietary Auto-Checks Technology runs internal checks and system calibrations throughout the analysis process to safeguard against sample loss and erroneous results. The analyser can also seamlessly transmit data via Wi-Fi or Ethernet to the provider’s LIS/HIS/EMR.
“Diabetes cases are rising, with estimates suggesting more than 780 million cases by 2045. By diagnosing early, we can help to prevent the health complications that occur when chronic conditions are left unmanaged," states Tobias Livingstone, Point of Care Business Lead at Siemens Healthineers Great Britain & Ireland. “The Atellica DCA Analyser enables HbA1c testing in a single interaction, supporting optimal diabetes management. This also minimises the barriers to care that patients may otherwise face if they needed to return to for further medical guidance after traditional testing."
More information on the Atellica DCA Analyser can be found here.
1 IDF diabetes atlas. 10th edition. Available from: http://www.diabetesatlas.org/
We need your consent to load the translations
We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.